Plus Therapeutics Stock Surges on Positive Clinical Developments

Plus Therapeutics shares are trading higher after the company announced progress in clinical trials for their REYOBIQ CNS cancer treatment and positive results from their CNSide CSF assay platform at the 2025 SNO/ASCO conference.